Relmada Therapeutics Announces Participation in Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Relmada Therapeutics, Inc. (Nasdaq: RLMD) has announced that CEO Sergio Traversa will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 10:30 am Eastern Time. The event will provide insights into the company's focus on treating central nervous system diseases, particularly major depressive disorder (MDD), with its lead program, REL-1017, currently in late-stage development. Participants can access the live webcast via the provided links, with an archived replay available for 30 days post-event.

Positive

• CEO participation in an influential healthcare conference enhances visibility.
• Focus on late-stage development of REL-1017 for major depressive disorder may attract investor interest.

Negative

• None.

NEW YORK, June 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, is scheduled to participate in a fireside chat at Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 10:30 am Eastern Time.

Participants may access a live webcast of the event through the following link:
https://wsw.com/webcast/jeff174/rlmd/1853145 

The webcast can also be accessed in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar. An archived replay of the event will be available for 30 days after the conclusion of the presentation.

About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.

Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564 
Tim@LifeSciAdvisors.com

Media Inquiries:
FischTank PR
Relmada@FischTankPR.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-participation-in-jefferies-virtual-healthcare-conference-301302650.html

SOURCE Relmada Therapeutics, Inc.

FAQ

When is Relmada Therapeutics' CEO scheduled to speak at the Jefferies Healthcare Conference?

Sergio Traversa, CEO of Relmada Therapeutics, is scheduled to speak on June 4, 2021, at 10:30 am Eastern Time.

Where can I watch the Relmada Therapeutics fireside chat?

The fireside chat can be accessed through a live webcast at the provided link and will also be available in the Investors section of Relmada's website.

What is REL-1017 being developed for?

REL-1017 is being developed as an adjunctive treatment for major depressive disorder (MDD) in adults.

How long will the webcast of Relmada's event be available?

An archived replay of the event will be available for 30 days after the conclusion of the presentation.

What is the significance of the Jefferies Virtual Healthcare Conference for Relmada Therapeutics?

Participation in the Jefferies Virtual Healthcare Conference allows Relmada Therapeutics to increase its visibility and potentially attract interest from investors and healthcare professionals.